Palisade Bio (PALI) announced that it dosed its first subject in its Phase 1 clinical study of PALI-2108, an orally administered PDE4 inhibitor prodrug that is locally bioactivated in the colon and is in development for patients affected by UC. The Phase 1 study will evaluate PALI-2108 in a single-center, double-blind, placebo-controlled study focused on safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers, alongside an open-label study involving a patient cohort with UC. Patient screening for the study is underway.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI:
- Palisade Bio announces data from two ex vivo studies of PALI-2108
- Palisade Bio files to sell common stock, warrants, no amount given
- Palisade Bio received No Objection Letter from Health Canada for Phase 1 study
- Palisade Bio CEO Finley’s Revised Employment and Compensation Deal
- Palisade Bio provides update on Phase 1 trial of PALI-2108
Questions or Comments about the article? Write to editor@tipranks.com